Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant ...

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other ...

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines. The pharmaceutical company said Monday that the new facility will be ...

US-based medicine company Eli Lilly to invest $3B in a new manufacturing facility in the Netherlands to expand production and create jobs.

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised ...

U .S. pharmaceutical company Eli Lilly (LLY) has announced plans to build a $3 billion manufacturing plant in the Netherlands ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and other oral medicines.

Eli Lilly and Company announced Wednesday, Oct. 29 a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.